Aggrecanases gene inhibition in chondrocytes: A new possible strategy to relieve immune rejection of transplants

Medical Hypotheses

Volumn 72, Issue 2, 2009, Pages 196-198

  Wang, Zhenghui ^a   Yang, Zhuangqun ^a   He, Xijing ^a   Tu, Junbo ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGGRECANASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE INJURY; CARTILAGE TRANSPLANTATION; CATABOLISM; CELL TRANSPLANTATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GRAFT REJECTION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE ENGINEERING;

CARTILAGE; CHONDROCYTES; ENDOPEPTIDASES; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMANS;

EID: 57749182684     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.07.061     Document Type: Article

References (27)

1. Yang Z.Q., Hou C.Q., Chang X.F., Wang Y., Xu Y.C., and Zheng X.M. Experimental observation on the dynamic changes of cartilage matrix in homografts. Chin J Aesthetic Med 6 1 (1997) 14-16
2. Hou C.Q., Yang Z.Q., Chang X.F., et al. An experimental study on changes in collagen content after homologous cartilage implantation. Chin J Plast Surg 11 4 (1995) 274-276
3. Zheng X.M., Yang Z.Q., Hou C.Q., Feng B., Wang Y., and Xu Y.C. Experimental observations of the quantitative change of proteoglycan in homogenous cartilage graft in the guinea pig. Chin J Plast Surg 11 (1995) 129-131
4. Eckardt A., Meyer A., Laas U., and Hausamen J.E. Reconstruction of defects in the head and neck with free flaps: 20 years experience. Br J Oral Maxillofac Surg 45 1 (2007) 11-15
5. Kermer C., Ziya-Ghazvini F., Poeschl P.W., and Klug C. Two stage reconstruction with revascularized grafts after resection of retromolar and oropharyngeal carcinoma. Int J Oral Maxillofac Surg 33 6 (2004) 554-557
6. Poeschl P.W., Kermer C., Wagner A., Klug C., Ziya-Ghazvini F., and Poeschl E. The radial free forearm flap-prelaminated versus non-prelaminated: a comparison of two methods. Int J Oral Maxillofac Surg 32 2 (2003) 159-166
7. Ehrler D.M., and Vaccaro A.R. The use of allograft bone in lumbar spine surgery. Clin Orthop Relat Res 371 (2000) 38-45
8. Ozaki T., Hillman A., Wuisman P., and Winkelmann W. Reconstruction of tibia by ipsilateral vascularized fibula and allograft-12 cases with malignant bone tumors. Acta Orthop Scand 68 3 (1997) 298-301
9. Romaniuk A., Malejczyk J., Kubicka U., Hyc A., Olszewski W., and Moskalewski S. Rejection of cartilage formed by transplanted allogeneic chondrocytes: evaluation with monoclonal antibodies. Transplant Immunol 3 (1995) 251-257
10. Temenoff J.S., and Mikos A.G. Review: tissue engineering for regeneration of articular cartilage. Biomaterials 21 5 (2000) 431-440
11. Hu R., Hearn T., and Yang J. Bone graft harvest site as a determinant of iliac crest strength. Clin Orthop Relat Res 310 (1995) 252-256
12. Giboson S., Mcleod I., Wardlaw D., and Urbaniak S. Allograft versus autograft in Instrumented posterolateral lumber spinal fusion: a randomized control trial. Spine 27 15 (2002) 1599-1603
13. Zheng X.M., Yang Z.Q., Hou C.Q., et al. The effects of cartilage matrix on cartilage implantation mechanisms. Chin J Plast Surg 15 (1999) 74-75
14. Liu H., Kemeny D.M., Heng B.C., Ouyang H.W., Melendez A.J., and Cao T. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 176 5 (2006) 2861-2871
15. Hardingham T.E., and Fosang A.J. Proteoglycans: many forms and many functions. FASEB J 6 (1992) 861-870
16. Vertel B.M. The ins and outs of aggrecan. Trends Cell Biol 5 (1995) 458-464
17. Mankin H.J., and Lippiello L. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am 52 (1970) 424-434
18. Lohmander L.S., Neame P.J., and Sandy J.D. The structure of aggrecan fragments in human synovial fluid evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 36 (1993) 1214-1222
19. Stokes D.G., Liu G., Coimbra I.B., Piera-Velazquez S., Crowl R.M., and Jimenez S.A. Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum 46 2 (2002) 404-419
20. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) in a model of cartilage degradation. Osteoarth Cartil 9 6 (2001) 539-552
21. Flannery C.R., Lark M.W., and Sandy J.D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 267 2 (1992) 1008-1014
22. 374 bond of the interglobular domain. J Clin Invest 89 5 (1992) 1512-1516
23. Collins-Racie L.A., Flannery C.R., Zeng W., et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 23 (2004) 219-230
24. Pratta M.A., Tortorella M.D., and Arner E.C. Age related changes in aggrecan glycosylation affect cleavage by aggrecanase. J Biol Chem 275 (2000) 39096-39102
25. Elizabeth C.A., Michael A.P., Carlp D., et al. Aggrecanase: a target for the design of inhibitors of cartilage degradation. Ann NY Acad Sci 30 (1999) 92-107
26. Arner E.C., Pratta M.A., Trzaskos J.M., Decicco C.P., and Tortorella M.D. Generation and characterization of aggrecanase A soluble, cartilage-derived aggrecan degrading activity. J Biol Chem 274 (1999) 6594-6601
27. Song R.H., Tortorella M.D., Malfait A.M., et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 56 (2007) 575-585